Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Teva
US Army
Deloitte
Healthtrust
Chubb
Daiichi Sankyo
AstraZeneca
Moodys

Generated: September 21, 2018

DrugPatentWatch Database Preview

Concordia Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for CONCORDIA PHARMS INC, and what generic alternatives to CONCORDIA PHARMS INC drugs are available?

CONCORDIA PHARMS INC has twelve approved drugs.

There are two US patents protecting CONCORDIA PHARMS INC drugs.

Summary for Concordia Pharms Inc
US Patents:2
Tradenames:13
Ingredients:11
NDAs:12

Drugs and US Patents for Concordia Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-003 Jun 1, 2006 AB RX Yes Yes 6,740,341 ➤ Sign Up Y ➤ Sign Up
Concordia Pharms Inc KAYEXALATE sodium polystyrene sulfonate POWDER;ORAL, RECTAL 011287-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up
Concordia Pharms Inc PARNATE tranylcypromine sulfate TABLET;ORAL 012342-003 Aug 16, 1985 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Concordia Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 6,024,981 ➤ Sign Up
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 6,221,392 ➤ Sign Up
Concordia Pharms Inc JENLOGA clonidine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022331-001 Sep 30, 2009 5,869,100 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for CONCORDIA PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 0.1 mg and 0.2 mg ➤ Subscribe 2011-03-04
➤ Subscribe Extended-release Tablets 10 mg ➤ Subscribe 2007-06-12
➤ Subscribe Orally Disintegrating Tablets 10 mg, 15 mg and 30 mg ➤ Subscribe 2010-07-22
➤ Subscribe Extended-release Tablets 0.1 mg and 0.2 mg ➤ Subscribe 2011-03-04

Supplementary Protection Certificates for Concordia Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB07/011 United Kingdom ➤ Sign Up PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
C/GB06/021 United Kingdom ➤ Sign Up PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
C0005 Belgium ➤ Sign Up PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Harvard Business School
US Department of Justice
Queensland Health
Boehringer Ingelheim
QuintilesIMS
Moodys
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.